CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $183,000 | +94.7% | 1,195 | +6.2% | 0.04% | +52.2% |
| Q3 2020 | $94,000 | +13.3% | 1,125 | 0.0% | 0.02% | +4.5% |
| Q2 2020 | $83,000 | +72.9% | 1,125 | -0.1% | 0.02% | +37.5% |
| Q1 2020 | $48,000 | +26.3% | 1,126 | +87.0% | 0.02% | +60.0% |
| Q4 2019 | $38,000 | +46.2% | 602 | 0.0% | 0.01% | +42.9% |
| Q3 2019 | $26,000 | +8.3% | 602 | +20.4% | 0.01% | 0.0% |
| Q2 2019 | $24,000 | +33.3% | 500 | 0.0% | 0.01% | +40.0% |
| Q1 2019 | $18,000 | +12.5% | 500 | 0.0% | 0.01% | 0.0% |
| Q4 2018 | $16,000 | -33.3% | 500 | 0.0% | 0.01% | -28.6% |
| Q3 2018 | $24,000 | -20.0% | 500 | 0.0% | 0.01% | -22.2% |
| Q2 2018 | $30,000 | – | 500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |